Another Big Pharma CEO is having a pep talk with employees about manufacturing lapses and the need to reflect on quality.
In its first-quarter earnings confab, J&J made good on CEO Alex Gorsky's pledge to get the company's troubled OTC manufacturing plants in shape and return the consumer health business to a growing top line.
On FierceMedicalDevices ' list of 2012's 10 highest-paid med tech CEOs, half are serving in their first full year on the job or are new in the position as of this year. Read the full report >>
The question isn't why Johnson & Johnson CEO Alex Gorsky took a 10% hit to his incentive pay. It's why Chairman William Weldon didn't suffer a bigger cut in his pay.
A big development in the diagnostics industry emerged in Johnson & Johnson's heavy stream of earnings news today. The healthcare giant ($JNJ) is mulling options for its Ortho Clinical Diagnostics business, as CEO Alex Gorsky moves to emphasize the company's best prospects for growth.
A consent decree and a $100 million investment to upgrade its key OTC plant have not led Johnson & Johnson to give up on its Fort Washington, PA, operations, CEO Alex Gorsky told investors today.
Alex Gorsky now has it all. The CEO of Johnson & Johnson today was named chairman of the drug and consumer products company, replacing Bill Weldon, who is retiring from J&J after four decades.
Another Big Pharma CEO faces the prospect of appearing before a jury to testify in defense of a drug that has been called dangerous.
Johnson & Johnson's $21.3 billion Synthes acquisition is starting to pay off, as the company reported a 12.5% third-quarter increase in medical device sales due largely to its fresh-bought orthopedics offerings.
Pfizer doesn't want CEO Ian Read to take the stand in a Chantix liability suit. That's not unusual; Johnson & Johnson fought a request that CEO Alex Gorsky testify in person in a trial over alleged Risperdal misconduct. What's different in Pfizer's case is that a judge actually ordered Read to appear.